文献速递药物不良反应与药物警戒

左乙拉西坦原研转仿制后因辅料发生严重皮肤不良反应

Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

本文报告一例29岁女性在左乙拉西坦从原研药换为仿制药一周后,发生中毒性表皮坏死松解症与药物反应伴嗜酸性粒细胞增多和全身症状重叠综合征的严重皮肤不良反应。分析认为仿制药辅料是可能原因,停药并重症监护2周后恢复。这是首例左乙拉西坦原研转仿制后严重皮肤药物过敏的报道。

要点

  • 左乙拉西坦原研转仿制可能因辅料差异引发严重过敏反应。
  • 换药后出现严重皮肤反应需立即停用并评估辅料致敏可能。
  • 严重皮肤不良反应可表现为TEN-DRESS重叠综合征。

核心结论

  • 左乙拉西坦从原研药换为仿制药后,可能因辅料差异导致严重皮肤药物过敏。

研究设计与样本

  • 个案报告:一例29岁女性患者。

主要发现

  • 患者在使用仿制左乙拉西坦一周后出现躯干皮损,进展为中毒性表皮坏死松解症与药物反应伴嗜酸性粒细胞增多和全身症状重叠综合征。
  • 停用左乙拉西坦并重症监护2周后恢复。
  • 不良反应分析提示仿制左乙拉西坦中的辅料为可能原因。

临床怎么用

  • 临床药师应关注原研转仿制换药时辅料差异可能引起的严重过敏反应。
  • 对换药后出现严重皮肤反应的患者,应及时停用可疑药物并评估辅料致敏。

局限性

  • 单个病例报告,因果关系推断受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Levetiracetam is an antiepileptic drug known for its high tolerability, and severe adverse drug reactions are rare. We report the case of a severe cutaneous adverse drug reaction in a patient who was switched from brand-name to generic levetiracetam. SUMMARY: A 29-year-old woman undergoing contrast-enhanced computed tomography developed lesions over her trunk starting 6 hours after imaging. Although initially diagnosed as an allergy to the radiocontrast agent, the condition progressively worsened into toxic epidermal necrolysis-drug reaction with eosinophilia and systemic symptoms overlap syndrome, despite adequate hydration and treatment. Investigation of the patient's medications revealed that she had been switched from brand-name to generic levetiracetam a week before the onset of symptoms. Levetiracetam was immediately discontinued, with the patient recovering after 2 weeks of intensive care. Adverse drug reaction analysis identified excipients in generic levetiracetam as the likely cause of the severe reaction. CONCLUSION: This is the first reported case of severe cutaneous drug allergy after a brand-to-generic switch for levetiracetam. Brand-to-generic switches of medications can potentially cause severe allergic reactions due to differences in excipients.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Lim JA, Jamil A, Ramli NA, et al. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. Am J Health Syst Pharm. 2024. PMID: 37864830. doi:10.1093/ajhp/zxad264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。